| SLCO4A1-AS1 triggers the malignant behaviours of melanoma cells via sponging miR-1306-5p to enhance PCGF2. | SLCO4A1-AS1 triggers the malignant behaviours of melanoma cells via sponging miR-1306-5p to enhance PCGF2.
Wang K, Li M, Duan H, Fan M, Xu C, Yu F. | 08/27/2022 |
| AKT-mediated regulation of chromatin ubiquitylation and tumorigenesis through Mel18 phosphorylation. | AKT-mediated regulation of chromatin ubiquitylation and tumorigenesis through Mel18 phosphorylation.
Mai J, Peng XD, Tang J, Du T, Chen YH, Wang ZF, Zhang HL, Huang JH, Zhong ZY, Yang D, Li ZL, Huang Y, Feng GK, Zhu XF, Deng R. | 10/23/2021 |
| Low expression of Mel-18 is correlated with gastric cancer. | Mel-18 negatively regulates stem cell-like properties through downregulation of miR-21 in gastric cancer.
Wang XF, Zhang XW, Hua RX, Du YQ, Huang MZ, Liu Y, Cheng YF, Guo WJ., Free PMC Article | 03/17/2018 |
| Suggest a novel role of PCGF2 in arsenic trioxide-mediated degradation of PML-RARA that PCGF2 might act as a negative regulator of UBE2I via direct interaction. | PCGF2 negatively regulates arsenic trioxide-induced PML-RARA protein degradation via UBE2I inhibition in NB4 cells.
Jo S, Lee YL, Kim S, Lee H, Chung H. | 09/10/2016 |
| Mel-18 underexpression in luminal breast cancer cells caused ER-alpha downregulation.Its overexpression restored it in triple-negative breast cancer cells. MEL-18 suppressed SUMOylation of the ESR1 transactivators p53 and SP1. | MEL-18 loss mediates estrogen receptor-α downregulation and hormone independence.
Lee JY, Won HY, Park JH, Kim HY, Choi HJ, Shin DH, Kang JH, Woo JK, Oh SH, Son T, Choi JW, Kim S, Kim HY, Yi K, Jang KS, Oh YH, Kong G., Free PMC Article | 08/22/2015 |
| It was therefore concluded that the lower Mel-18 expression might contribute to colorectal cancer development/progression. | Expression and clinicopathological significance of Mel-18 mRNA in colorectal cancer.
Tao J, Liu YL, Zhang G, Ma YY, Cui BB, Yang YM. | 01/10/2015 |
| Mel-18 functions as a tumor suppressor by its novel negative control of the epithelial-mesenchymal transition in breast cancer. | Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer.
Lee JY, Park MK, Park JH, Lee HJ, Shin DH, Kang Y, Lee CH, Kong G. | 05/3/2014 |
| Findings suggest that Mel-18 is a novel negative regulator of breast cancer stem cell (CSC) that inhibits the stem cell population and in vitro and in vivo self-renewal through the inactivation of Wnt-mediated Notch signaling. | Loss of Mel-18 enhances breast cancer stem cell activity and tumorigenicity through activating Notch signaling mediated by the Wnt/TCF pathway.
Won HY, Lee JY, Shin DH, Park JH, Nam JS, Kim HC, Kong G. | 04/13/2013 |
| PCGF2, a PRC1 gene, played a negative role in the granulocytic differentiation of human APL cells. | Inhibition of PCGF2 enhances granulocytic differentiation of acute promyelocytic leukemia cell line HL-60 via induction of HOXA7.
Jo S, Lee H, Kim S, Hwang EM, Park JY, Kang SS, Chung H. | 01/28/2012 |
| these findings provide that Mel-18 is a novel regulator of tumor angiogenesis through regulating HIF-1alpha and its target VEGF expressions mediated by the PTEN/PI3K/Akt pathway, suggesting a new tumor-suppressive role of Mel-18 in human breast cancer. | Loss of Mel-18 induces tumor angiogenesis through enhancing the activity and expression of HIF-1α mediated by the PTEN/PI3K/Akt pathway.
Park JH, Lee JY, Shin DH, Jang KS, Kim HJ, Kong G. | 01/14/2012 |
| Loss of Mel-18 is associated with prostate cancer. | Analysis of Mel-18 expression in prostate cancer tissues and correlation with clinicopathologic features.
Wang W, Lin T, Huang J, Hu W, Xu K, Liu J. | 10/1/2011 |
| Our analysis showed correlation between BMI1 and PCGF2 gene's expression and survival in children with medulloblastoma. | Polycomb genes expression as a predictor of poor clinical outcome in children with medulloblastoma.
Zakrzewska M, Zakrzewski K, Grešner SM, Piaskowski S, Zalewska-Szewczyk B, Liberski PP., Free PMC Article | 04/30/2011 |
| Bmi-1/Mel-18 ratio can be potentially used as a tool for stratifying women at risk of developing breast malignancy. | Expression of BMI-1 and Mel-18 in breast tissue--a diagnostic marker in patients with breast cancer.
Riis ML, Lüders T, Nesbakken AJ, Vollan HS, Kristensen V, Bukholm IR., Free PMC Article | 04/2/2011 |
| Mel-18 may serve as a useful marker in prognostic evaluation for patients with breast cancer. | Low expression of Mel-18 predicts poor prognosis in patients with breast cancer.
Guo BH, Zhang X, Zhang HZ, Lin HL, Feng Y, Shao JY, Huang WL, Kung HF, Zeng MS. | 03/19/2011 |
| Decreased Mel-18 and increased Bmi-1 mRNA expression was associated with the carcinogenesis and progression of gastric cancer | Expression and clinicopathological significance of Mel-18 and Bmi-1 mRNA in gastric carcinoma.
Lu YW, Li J, Guo WJ., Free PMC Article | 03/19/2011 |
| An association of Mel18 with emerin was observed in Hutchinson-Gilford progeria syndrome, but not in WT cells. | Association of progerin-interactive partner proteins with lamina proteins: Mel18 is associated with emerin in HGPS.
Ju WN, Brown WT, Zhong N. | 01/29/2011 |
| Mel-18 plays a significant role in the angiogenic function of endothelial cells by regulating endothelial gene expression. | Mel-18, a mammalian Polycomb gene, regulates angiogenic gene expression of endothelial cells.
Jung JH, Choi HJ, Maeng YS, Choi JY, Kim M, Kwon JY, Park YW, Kim YM, Hwang D, Kwon YG. | 11/27/2010 |
| BMI1 acts as an oncogene and Mel-18 functions as a tumor suppressor via downregulation of BMI1. | BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer.
Zhang XW, Sheng YP, Li Q, Qin W, Lu YW, Cheng YF, Liu BY, Zhang FC, Li J, Dimri GP, Guo WJ., Free PMC Article | 05/31/2010 |
| Single Nucleotide Polymorphism and down regulation of Mel-18 is associated with prostate cancer. | The novel tumor-suppressor Mel-18 in prostate cancer: its functional polymorphism, expression and clinical significance.
Wang W, Yuasa T, Tsuchiya N, Ma Z, Maita S, Narita S, Kumazawa T, Inoue T, Tsuruta H, Horikawa Y, Saito M, Hu W, Ogawa O, Habuchi T, Wang W, Yuasa T, Tsuchiya N, Ma Z, Maita S, Narita S, Kumazawa T, Inoue T, Tsuruta H, Horikawa Y, Saito M, Hu W, Ogawa O, Habuchi T. | 01/21/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | The novel tumor-suppressor Mel-18 in prostate cancer: its functional polymorphism, expression and clinical significance.
Wang W, Yuasa T, Tsuchiya N, Ma Z, Maita S, Narita S, Kumazawa T, Inoue T, Tsuruta H, Horikawa Y, Saito M, Hu W, Ogawa O, Habuchi T, Wang W, Yuasa T, Tsuchiya N, Ma Z, Maita S, Narita S, Kumazawa T, Inoue T, Tsuruta H, Horikawa Y, Saito M, Hu W, Ogawa O, Habuchi T. | 08/12/2009 |
| The results of this study strengthen the conclusion that mel-18 functions as an anti-SUMO E3 factor, and extend its targets to include regulation of the sumoylation of the important cellular protein RanGAP1. | Mel-18 interacts with RanGAP1 and inhibits its sumoylation.
Zhang J, Sarge KD., Free PMC Article | 01/21/2010 |
| Results show that a phosphorylated form of Mel-18 targets the Ring1B histone H2A ubiquitin ligase to chromatin. | A phosphorylated form of Mel-18 targets the Ring1B histone H2A ubiquitin ligase to chromatin.
Elderkin S, Maertens GN, Endoh M, Mallery DL, Morrice N, Koseki H, Peters G, Brockdorff N, Hiom K. | 01/21/2010 |
| The oncogenic role of MEL-18 in human primary breast carcinomas is determined by its capacity to inhibit INK4a/ARF proteins(p16INK4a, p14ARF, or h-TERT) or to induce telomerase activity. | Implication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas.
Silva J, García JM, Peña C, García V, Domínguez G, Suárez D, Camacho FI, Espinosa R, Provencio M, España P, Bonilla F. | 01/21/2010 |
| validated occurrence of an unusual TG 3' splice site in intron 1 | Violating the splicing rules: TG dinucleotides function as alternative 3' splice sites in U2-dependent introns.
Szafranski K, Schindler S, Taudien S, Hiller M, Huse K, Jahn N, Schreiber S, Backofen R, Platzer M., Free PMC Article | 10/9/2007 |
| Mel-18 and Bmi-1 may regulate the Akt pathway in breast cancer cells, and that Mel-18 functions as a tumor suppressor by repressing the expression of Bmi-1 and consequently down-regulating Akt activity. | Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells.
Guo WJ, Zeng MS, Yadav A, Song LB, Guo BH, Band V, Dimri GP., Free PMC Article | 01/21/2010 |